bioengineering-10-00076
Citation
Kaur, G.; Verma, S.K.; Singh, D.; Singh, N.K. Role of G-Proteins and GPCRs in Cardiovascular Pathologies. Bioengineering 2023, 10, 76.
Received: 5 November 2022, Published: 6 January 2023
Copyright © 2023 by the authors.
Overview of G-Proteins and GPCRs
G-Proteins: Specialized proteins that bind to nucleotides (GTP and GDP); two types: monomeric and heterotrimeric.
GPCRs (G-Protein-Coupled Receptors): Transmit signals for various physiological functions and are crucial in cardiovascular pathologies.
Importance of Cardiovascular Diseases (CVDs)
CVDs cause significant global morbidity and mortality, accounting for 31% of all deaths (approx. 17.9 million annually).
Include disorders like coronary heart disease, myocardial infarction, and stroke.
Complex pathophysiology influenced by various cellular processes and intrinsic/extrinsic factors.
G-Proteins Structure and Function
Composed of subunits: Gα (stimulatory or inhibitory), Gβ, and Gγ; Gα proteins divided into groups (e.g., Gαs, Gαi).
Act as molecular switches; active state (bound with GTP) vs. inactive state (GDP bound).
Regulate processes like cell growth, synthesis, and signaling pathways through various downstream effectors.
Role in Cardiovascular Diseases
G-proteins are involved in signaling pathways affecting cardiovascular function and disease progression.
Heart Failure: Changes in GPCR signaling lead to improper heart response; downregulation of β1 receptors and increased Gi proteins contribute to worsening conditions.
Myocardial Ischemia: Imbalance of oxygen supply and demand; GPCRs, particularly adrenergic receptors, play an essential role in this process.
Hypertension: The balance between vasoconstrictors and vasodilators is crucial; dysregulation leads to increased blood pressure.
Atherosclerosis: Involves receptor interactions and plaque development; G-proteins participate in endothelial dysfunction.
Stroke & PAD: G-proteins influence pathways leading to ischemia and vascular remodeling.
Key Mechanisms and Therapies
Regulation of GPCR activity via agonists, inverse agonists, and antagonists affects G-protein activation.
Potential therapeutic targets in drugs for heart failure, hypertension, and other cardiovascular conditions include GPCR modulators (e.g., β-blockers, ACE inhibitors).
Exploration of G-protein signaling in drug development aims to improve specificity and efficacy of treatments.